Logo image of ICAD.PA

ICADE (ICAD.PA) Stock Fundamental Analysis

Europe - EPA:ICAD - FR0000035081 - REIT

20.46 EUR
+0.2 (+0.99%)
Last: 10/9/2025, 7:00:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ICAD. ICAD was compared to 42 industry peers in the Diversified REITs industry. Both the profitability and financial health of ICAD have multiple concerns. ICAD is valued quite cheap, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

In the past year ICAD was profitable.
In the past year ICAD had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: ICAD reported negative net income in multiple years.
ICAD had a positive operating cash flow in each of the past 5 years.
ICAD.PA Yearly Net Income VS EBIT VS OCF VS FCFICAD.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M -1B

1.2 Ratios

The Return On Assets of ICAD (-1.85%) is worse than 76.19% of its industry peers.
With a Return On Equity value of -4.79%, ICAD is not doing good in the industry: 78.57% of the companies in the same industry are doing better.
The Return On Invested Capital of ICAD (2.76%) is worse than 69.05% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for ICAD is in line with the industry average of 3.40%.
The last Return On Invested Capital (2.76%) for ICAD is above the 3 year average (2.14%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA -1.85%
ROE -4.79%
ROIC 2.76%
ROA(3y)-4.37%
ROA(5y)-2.07%
ROE(3y)-10.21%
ROE(5y)-4.69%
ROIC(3y)2.14%
ROIC(5y)2.38%
ICAD.PA Yearly ROA, ROE, ROICICAD.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20

1.3 Margins

ICAD has a Operating Margin of 19.60%. This is amonst the worse of the industry: ICAD underperforms 83.33% of its industry peers.
In the last couple of years the Operating Margin of ICAD has declined.
The Profit Margin and Gross Margin are not available for ICAD so they could not be analyzed.
Industry RankSector Rank
OM 19.6%
PM (TTM) N/A
GM N/A
OM growth 3Y-28.23%
OM growth 5Y-3.84%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ICAD.PA Yearly Profit, Operating, Gross MarginsICAD.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ICAD is destroying value.
Compared to 1 year ago, ICAD has about the same amount of shares outstanding.
ICAD has more shares outstanding than it did 5 years ago.
ICAD has a worse debt/assets ratio than last year.
ICAD.PA Yearly Shares OutstandingICAD.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ICAD.PA Yearly Total Debt VS Total AssetsICAD.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

Based on the Altman-Z score of 0.64, we must say that ICAD is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ICAD (0.64) is comparable to the rest of the industry.
The Debt to FCF ratio of ICAD is 45.49, which is on the high side as it means it would take ICAD, 45.49 years of fcf income to pay off all of its debts.
ICAD has a worse Debt to FCF ratio (45.49) than 78.57% of its industry peers.
ICAD has a Debt/Equity ratio of 0.97. This is a neutral value indicating ICAD is somewhat dependend on debt financing.
ICAD's Debt to Equity ratio of 0.97 is on the low side compared to the rest of the industry. ICAD is outperformed by 73.81% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.97
Debt/FCF 45.49
Altman-Z 0.64
ROIC/WACC0.99
WACC2.8%
ICAD.PA Yearly LT Debt VS Equity VS FCFICAD.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B

2.3 Liquidity

ICAD has a Current Ratio of 1.06. This is a normal value and indicates that ICAD is financially healthy and should not expect problems in meeting its short term obligations.
With an excellent Current ratio value of 1.06, ICAD belongs to the best of the industry, outperforming 80.95% of the companies in the same industry.
ICAD has a Quick Ratio of 1.06. This is a bad value and indicates that ICAD is not financially healthy enough and could expect problems in meeting its short term obligations.
With a decent Quick ratio value of 0.81, ICAD is doing good in the industry, outperforming 76.19% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.06
Quick Ratio 0.81
ICAD.PA Yearly Current Assets VS Current LiabilitesICAD.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

1

3. Growth

3.1 Past

The earnings per share for ICAD have decreased strongly by -72.25% in the last year.
Measured over the past years, ICAD shows a decrease in Earnings Per Share. The EPS has been decreasing by -9.69% on average per year.
The Revenue for ICAD has decreased by -13.82% in the past year. This is quite bad
Measured over the past years, ICAD shows a small growth in Revenue. The Revenue has been growing by 0.64% on average per year.
EPS 1Y (TTM)-72.25%
EPS 3YN/A
EPS 5Y-9.69%
EPS Q2Q%-10.91%
Revenue 1Y (TTM)-13.82%
Revenue growth 3Y-1.82%
Revenue growth 5Y0.64%
Sales Q2Q%-74.49%

3.2 Future

ICAD is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -1.60% yearly.
Based on estimates for the next years, ICAD will show a decrease in Revenue. The Revenue will decrease by -1.36% on average per year.
EPS Next Y10.6%
EPS Next 2Y2.29%
EPS Next 3Y-1.6%
EPS Next 5YN/A
Revenue Next Year-6.62%
Revenue Next 2Y-1.93%
Revenue Next 3Y-1.36%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ICAD.PA Yearly Revenue VS EstimatesICAD.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 500M 1B 1.5B
ICAD.PA Yearly EPS VS EstimatesICAD.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3 4 5

7

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 6.87, the valuation of ICAD can be described as very cheap.
Based on the Price/Earnings ratio, ICAD is valued cheaply inside the industry as 95.24% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 27.70. ICAD is valued rather cheaply when compared to this.
A Price/Forward Earnings ratio of 6.19 indicates a rather cheap valuation of ICAD.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ICAD indicates a rather cheap valuation: ICAD is cheaper than 95.24% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.15, ICAD is valued rather cheaply.
Industry RankSector Rank
PE 6.87
Fwd PE 6.19
ICAD.PA Price Earnings VS Forward Price EarningsICAD.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ICAD is valued cheaper than 95.24% of the companies in the same industry.
The rest of the industry has a similar Price/Free Cash Flow ratio as ICAD.
Industry RankSector Rank
P/FCF 15.17
EV/EBITDA 10.35
ICAD.PA Per share dataICAD.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.65
PEG (5Y)N/A
EPS Next 2Y2.29%
EPS Next 3Y-1.6%

4

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 5.40%, ICAD is a good candidate for dividend investing.
ICAD's Dividend Yield is comparable with the industry average which is at 5.55.
Compared to an average S&P500 Dividend Yield of 2.44, ICAD pays a better dividend.
Industry RankSector Rank
Dividend Yield 5.4%

5.2 History

The dividend of ICAD has a limited annual growth rate of 1.04%.
Dividend Growth(5Y)1.04%
Div Incr Years1
Div Non Decr Years1
ICAD.PA Yearly Dividends per shareICAD.PA Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 2 4 6

5.3 Sustainability

The earnings of ICAD are negative and hence is the payout ratio. ICAD will probably not be able to sustain this dividend level.
DP-185.46%
EPS Next 2Y2.29%
EPS Next 3Y-1.6%
ICAD.PA Yearly Income VS Free CF VS DividendICAD.PA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B

ICADE

EPA:ICAD (10/9/2025, 7:00:00 PM)

20.46

+0.2 (+0.99%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryDiversified REITs
Earnings (Last)07-23 2025-07-23/amc
Earnings (Next)10-22 2025-10-22
Inst Owners73.36%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap1.56B
Analysts69.47
Price Target24.85 (21.46%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 5.4%
Yearly Dividend4.84
Dividend Growth(5Y)1.04%
DP-185.46%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.35%
PT rev (3m)-4.12%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.02%
EPS NY rev (3m)3.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.36%
Revenue NY rev (3m)2.31%
Valuation
Industry RankSector Rank
PE 6.87
Fwd PE 6.19
P/S 1.04
P/FCF 15.17
P/OCF 4.75
P/B 0.4
P/tB 0.4
EV/EBITDA 10.35
EPS(TTM)2.98
EY14.57%
EPS(NY)3.31
Fwd EY16.16%
FCF(TTM)1.35
FCFY6.59%
OCF(TTM)4.31
OCFY21.06%
SpS19.67
BVpS51.19
TBVpS50.76
PEG (NY)0.65
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.85%
ROE -4.79%
ROCE 3.87%
ROIC 2.76%
ROICexc 3.38%
ROICexgc 3.4%
OM 19.6%
PM (TTM) N/A
GM N/A
FCFM 6.86%
ROA(3y)-4.37%
ROA(5y)-2.07%
ROE(3y)-10.21%
ROE(5y)-4.69%
ROIC(3y)2.14%
ROIC(5y)2.38%
ROICexc(3y)2.49%
ROICexc(5y)2.67%
ROICexgc(3y)2.5%
ROICexgc(5y)2.68%
ROCE(3y)3.06%
ROCE(5y)3.38%
ROICexcg growth 3Y-8.78%
ROICexcg growth 5Y2.92%
ROICexc growth 3Y-8.79%
ROICexc growth 5Y2.96%
OM growth 3Y-28.23%
OM growth 5Y-3.84%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.15
Health
Industry RankSector Rank
Debt/Equity 0.97
Debt/FCF 45.49
Debt/EBITDA 9.41
Cap/Depr 211.04%
Cap/Sales 15.05%
Interest Coverage 4.1
Cash Conversion 81.96%
Profit Quality N/A
Current Ratio 1.06
Quick Ratio 0.81
Altman-Z 0.64
F-Score5
WACC2.8%
ROIC/WACC0.99
Cap/Depr(3y)678.24%
Cap/Depr(5y)1255.8%
Cap/Sales(3y)20.42%
Cap/Sales(5y)31.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-72.25%
EPS 3YN/A
EPS 5Y-9.69%
EPS Q2Q%-10.91%
EPS Next Y10.6%
EPS Next 2Y2.29%
EPS Next 3Y-1.6%
EPS Next 5YN/A
Revenue 1Y (TTM)-13.82%
Revenue growth 3Y-1.82%
Revenue growth 5Y0.64%
Sales Q2Q%-74.49%
Revenue Next Year-6.62%
Revenue Next 2Y-1.93%
Revenue Next 3Y-1.36%
Revenue Next 5YN/A
EBIT growth 1Y74.88%
EBIT growth 3Y-29.53%
EBIT growth 5Y-3.23%
EBIT Next Year51.07%
EBIT Next 3Y14.51%
EBIT Next 5Y8.67%
FCF growth 1Y240.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-17.57%
OCF growth 3Y-11.53%
OCF growth 5Y-0.14%